Cost-Utility Analysis Of Erythropoietin For Hemodialysis Patients

Published Jun 30, 2014
Bangkok, Thailand - Most patients receiving hemodialysis (HD) for end-stage renal disease (ESRD) currently receive erythropoietin (EPO) for anemia treatment. The goal of therapy is to achieve specific hemoglobin (Hb) target levels. Higher doses of EPO are used to attain higher target levels, but the appropriate Hb level is still controversial. Target Hb levels in chronic kidney disease (CKD) remain uncertain because Hb target levels above 13 g/dl have been associated with both benefit (quality of life) and harm (cardiovascular events). Researchers from the Faculty of Pharmaceutical Science at Chulalongkorn University and the Faculty of Medicine at Siriraj Hospital, Mahidol University in Thailand compared the cost utility of using EPO to maintain different Hb target levels in hemodialysis patients from a societal perspective. The results of the study, “Cost Utility Analysis of Erythropoietin for Anemia Treatment in Thai ESRD Patients with Hemodialysis,” show that the incremental cost-effectiveness ratios of Hb levels of more than 9 to 10, > 10 to 11, > 11 to 12, and >12 g/dl compared with the least costly option (Hb> 9 g/dl) were US$24,128.03, US$18,789.07, US$22,427.36, and US$28,022.33 per quality-adjusted life-year, respectively. For the Thai hemodialysis patient, providing EPO for a hemoglobin level of more than 10 to 11 g/dl was more cost-effective than other hemoglobin levels. “Erythropoietin is an expensive therapy and it has created an economic burden on the health care system of Thailand. Erythropoietin is essential for hemodialysis patients, but the appropriate Hb level is still uncertain. Thus, the decision to treat anemia in hemodialysis patients depends on the best practice guidelines that physicians rely on. In order to convince physicians or policy makers to take action for the appropriate Hb level, they need strong evidence-based research on the most cost-effective Hb level,” says Dr. Tanita Thaweethamcharoen, MPharm, PhD, Pharmacist and Health Economist at the Siriraj Hospital Health Policy Unit at Mahidol University in Bangkok, Thailand.

Value in Health Regional Issues (ISSN 2212-1099) is a scientific journal that encourages and enhances the science of pharmacoeconomic/health economic and health outcomes research and its use in health care decisions. The journal is published up to three times a year with one issue focusing on the Asia region, one issue focusing on the Latin America region, and one issue focusing on the Central & Eastern Europe, Western Asia and Africa regions.

The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is a nonprofit, international, educational and scientific organization that strives to increase the efficiency, effectiveness, and fairness of health care resource use to improve health.

Follow Value in Health Regional Issues on Twitter: @ISPORJournals

Related Stories

Value in Health Regional Issues Expands Editorial Scope and Reveals Plans to Transition to Gold Open Access Model

Jan 23, 2024

Value in Health Regional Issues, an official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced the expansion of its editorial scope and its plan to transition to a gold open access journal.

Empowering Change: Transforming Health Systems in Low- and Middle-Income Countries

Jan 22, 2024

ISPOR announced the publication of a special themed section of research papers in Value in Health Regional Issues that highlight innovative approaches to improving health outcomes in low- and middle-income countries through partnerships between health economics researchers and policy makers.

ISPOR’s Value in Health Regional Issues Receives Its First Impact Factor Score

Aug 7, 2023

Value in Health Regional Issues, the regionally focused journal of ISPOR, received its first-ever impact factor score this year. Value in Health, one of the top-ranked journals in the HEOR field, maintained its high ranking on the prestigious list of scholarly journals.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on Update my browser now